THERANEXUS: THERANEXUS EXTENDS THE CAPABILITIES OF NEUROLEAD, ITS ACTIVE AGENT SCREENING PLATFORM, TO AUTOPHAGY AND NEUROLOGICAL LYSOSOMAL STORAGE DISORDERS
(1) Lyon, 9 March 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announced that it has extended the capabilities of Neurolead, its drug candidate discovery platform, to include autophagy and neurological manifestations of lysosomal storage disorders. Neurolead, which combines the latest innovations in neuroscience and artificial...
France General Haute Normandie Mathieu Charv Lysosomal Storage Disorders Association Atomic Energy Commission Theranexus Chief Scientific
Source: finanznachrichten.de